Loring Wolcott & Coolidge Fiduciary Advisors’s Array Biopharma Inc ARRY Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,550	Closed	-$303K	–	761
2019 Q2	$303K	Hold	6,550	–	–	﹤0.01%	228
2019 Q1	$160K	Hold	6,550	–	–	﹤0.01%	276
2018 Q4	$93K	Hold	6,550	–	–	﹤0.01%	330
2018 Q3	$100K	Hold	6,550	–	–	﹤0.01%	350
2018 Q2	$110K	Buy	6,550 +550	+9%	+$8.75K	﹤0.01%	344
2018 Q1	$98K	Hold	6,000	–	–	﹤0.01%	369
2017 Q4	$77K	Hold	6,000	–	–	﹤0.01%	392
2017 Q3	$74K	Hold	6,000	–	–	﹤0.01%	389
2017 Q2	$45K	Hold	6,000	–	–	﹤0.01%	427
2017 Q1	$54K	Buy	+6,000	New	+$63.8K	﹤0.01%	403

Other funds holding ARRY

ASN

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's ARRY Position: Q3 2019 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 6,550 shares — an estimated $303K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in ARRY in Q1 2017 and held it in 10 quarters. The position peaked at $303K in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 6,550 Array Biopharma Inc shares in Q3 2019, an estimated $303K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Array Biopharma Inc in Q1 2017 and held it in 10 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Array Biopharma Inc position peaked at $303K in Q2 2019.
1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.